Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy

Table 1 Drug classes and corresponding risks of HBV reactivation[49,67]

Drug class	Drug	Risk of HBV reactivation for HBsAg-positive patients	Risk of HBV reactivation for HBsAg-negative/anti-HBc-positive patients
Monoclonal antibody	Rituximab	High (30%-60%)	High (> 10%)
	Ofatumumab
	Obinutuzumab
Anthracycline chemotherapy	Doxorubicin	High (15%-30%)	High (> 10%)
	Epirubicin
	Daunorubicin
Corticosteroids	High dose, e.g., Prednisolone ≥ 20 mg for ≥ 4 wk	High (> 10%)	Not available
	Moderate dose, e.g., Prednisolone < 20 mg for ≥ 4 wk	Moderate (1%-10%)	Moderate (1%-10%)
	Low dose, e.g., Prednisolone < 1 wk	Low (< 1%)	Low (< 1%)
Tyrosine kinase inhibitors	Imatinib, nilotinib	Moderate (1%-10%)	Moderate (1%-10%)
Traditional immunosuppressive agents	Methotrexate, azathioprine, 6-mercaptopurine	Low (< 1%)	Low (< 1%)

HBV: Hepatitis B virus.